Eiger BioPharmaceuticals, Inc. announced the appointment of Eldon Mayer as Executive Vice President and Chief Commercial Officer. Mr. Mayer is a pharmaceutical industry veteran with broad commercial experience in large and specialty pharma across multiple therapeutic areas, including both orphan and larger markets, with multiple successful exits by acquisition. Eiger concurrently announced that Mr. Mayer has resigned from its Board to focus on his new role as a member of the executive team. Eldon Mayer was most recently Executive Vice President and Chief Commercial Officer of Rigel Pharmaceuticals where he built and led the commercial organization of over 60 people and the successful launch of Tavalisse (fostamatinib disodium hexahydrate) for chronic immune thrombocytopenia, a rare disease.